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Background: Direct detection of the gene mutation al-
lows for the confirmation of the clinical diagnosis of
Machado-Joseph disease (MJD), the most frequent cause
of autosomal dominant spinocerebellar ataxia worldwide.
Objective: To address the main difficulties in our na-
tional MJD predictive testing program. The first was the
emergence of intermediate alleles, for which it is not yet
possible to determine whether they will cause disease.
The second was the issue of homoallelism, ie, homozy-
gosity for 2 normal alleles with exactly the same (CAG)n
length, which occurs in about 10% of all test results.
Methods: A large pedigree with 1 affected patient car-
rying a 71 and a 51 CAG repeat and 2 asymptomatic rela-
tives carrying the 51 CAG repeat and normal-size alle-
les underwent clinical and molecular studies. Intragenic
haplotypes for these alleles were determined. A repre-
sentative sample of the healthy population in the region
was obtained to assess the distribution of the normal
(CAG)n length. We established the genotype for 4 intra-
genic polymorphisms in the gene for MJD (MJD1) in 21
homoallelic individuals, to distinguish their 2 normal
chromosomes. In addition, we developed a new South-
ern blot method to completely exclude cases of nonam-
plification of expanded alleles in the homoallelic indi-
viduals.
Results: The study of the family in which the 51 CAG
repeat was found suggests that the allele is apparently not
associated with disease. These intermediate alleles were
not present in a large sample of the healthy population
from the same region. Intragenic polymorphisms al-
lowed distinction of the 2 different normal alleles in all
cases of homoallelism. The absence of an expanded al-
lele was also confirmed by Southern blot.
Conclusions: We propose an improved protocol for mo-
lecular testing for MJD. These strategies, developed to
overcome the practical difficulties mostly in the pre-
symptomatic and prenatal diagnosis of MJD, should prove
useful for other polyglutamine-related disorders.
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M ACHADO-JOSEPH dis-ease (MJD) is a pro-gressive, adult-onset,neurodegenerative dis-order transmitted in an
autosomal dominant manner that affects the
central nervous system. Its manifestations
include cerebellar ataxia and progressive
external ophthalmoplegia, associated in a
variable degree with pyramidal signs, ex-
trapyramidal signs (dystonia or rigidity),
amyotrophy, and peripheral neuropathy.1
The gene associated with this disease, MJD1,
was cloned in 1994, and the causative mu-
tation was shown to be the expansion of a
(CAG)n tract within its coding region.2 This
tract contains 12 to 44 triplets in healthy
individuals and from 61 to 87 in patients,
as shown in numerous studies of popula-
tions of diverse ethnic origin.2-22
Machado-Joseph disease is highly pleo-
morphic in its clinical presentation, and that
led to the definition of the following 3 sub-
phenotypes23: type 2, the most common,
characterized by cerebellar ataxia, ophthal-
moplegia, pyramidal signs, and onset in
midadulthood (mean age, 40.5 years);
type 1, the most severe form, character-
ized by an earlier onset (mean age, 24.3
years), marked spasticity, and dystonic fea-
tures in addition to the cerebellar ataxia and
ophthalmoplegia; and type 3, correspond-
ing to the mildest form, characterized by a
later onset (mean age, 46.8 years ) and
marked peripheral amyotrophies in addi-
tion to the main signs. A fourth (rare) sub-
phenotype characterized by the presence of
parkinsonian features, was also pro-
posed.24 This variable clinical presentation
is partly explained by the length of the ex-
panded allele. The inverse correlation ob-
served between age at onset and (CAG)n
length, however, is not sufficient to be
applicable in presymptomatic testing.3,25,26
There is, at present, no effective treat-
ment for MJD. Although the identification
of the causative gene has increased our un-
derstanding of the pathogenesis of MJD, the
detailed pathways that lead to neurodegen-
eration are still not clear, hampering the de-
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velopment of new therapies. Therefore, predictive testing
and genetic counseling are still the only means to dimin-
ish the impact of the disease in affected families.
Direct detection of the MJD mutation allows the con-
firmation of the clinical diagnosis, which can be useful
given the potential clinical overlap among the different
forms of spinocerebellar ataxia.27 Another immediate ap-
plication of the molecular test was the possibility of pre-
symptomatic diagnosis, in the context of genetic coun-
seling programs. This is of utmost importance, particularly
in areas of high prevalence of disease, such as the Azorean
islands (1:3700 in Sa˜o Miguel; 1:120 in Flores), where
the disease is considered a public health problem, and
some areas of mainland Portugal (1:1000 in a small area
of the Tagus River Valley).28,29 In this study, we address
the main difficulties encountered in the context of the
Portuguese Predictive Testing and Genetic Counseling
Program for Machado-Joseph Disease. The first was the
emergence of alleles of a size between the known nor-
mal and pathogenic ranges (intermediate alleles), for
which it is not possible at this point to determine whether
they will cause the disease. The second was the issue of
SUBJECTS, MATERIALS,
AND METHODS
SUBJECTS
A family from the Tagus River Valley (family MJD75)
was identified during an ongoing survey of inherited
ataxias in Portugal.29 Results of molecular testing
showed the proband and his 45-year-old affected son to
carry an expanded allele at the MJD1 gene; however, the
son also carried another allele of intermediate size, never
previously described in the affected or the healthy popu-
lation (Figure 1). To clarify the possible association of
this allele with the presence or absence of disease, an
important issue for genetic counseling of the family (in-
cluding the 2 asymptomatic siblings), we examined
additional members of the family, including the pro-
band’s spouse and 12 of her relatives (pedigree MJD75b)
(Figure 2).
To determine the (CAG)n size in normal chromosomes
and look for intermediate alleles, we tested anonymous Guth-
rie cards (from the national program for phenylketonuria
screening); 20 samples were collected at random from 16 vil-
lages in the region, totaling 320 chromosomes tested.
During a 2-year period, the molecular diagnosis of MJD
was obtained at our laboratory for 149 patients referred by
a neurologist or another physician, and for 55 at-risk fam-
ily members after indication by a medical geneticist. Of these
204 subjects, 21 were shown to be homoallelic and under-
went studies for intragenic polymorphisms and Southern
blot analysis as described herein.
MOLECULAR CHARACTERIZATION OF THE CAG
REPETITIVE TRACT AND INTRAGENIC
POLYMORPHISMS IN THE MJD1 GENE
Blood samples were obtained after informed consent from
all individuals in the familial study, and genomic DNA was
extracted from lymphocytes, as described elsewhere.30 The
DNA was extracted from the filter paper blots using the resin
Chelex (Bio-Rad, Hercules, Calif) in a final concentration
of 0.8%.
Amplification of the CAG repeat–containing frag-
ment in the MJD1 gene was performed by means of poly-
merase chain reaction (PCR) analysis, using previously de-
scribed conditions,2 and the size of the PCR products was
determined by denaturing 6% polyacrylamide gel electro-
phoresis in parallel with an M13 sequence ladder, visual-
ized by means of autoradiography. In every reaction, we
used as a positive control genomic DNA from a patient with
an expanded allele containing 86 CAG repeats, the largest
we have ever amplified by means of PCR.
The intragenic polymorphisms C987GG/G987GG and
TAA1118/TAC1118 (single nucleotide substitutions at posi-
tions indicated in each codon) were detected by means of
allele-specific PCR.31 The polymorphism A669TG/G669TG
was detected by means of single-strand conformational
polymorphism analysis.31 The intragenic polymorphism
C1178/A1178 (single nucleotide substitution at position 1178
in the 3 noncoding region of the gene) was detected
by means of allele-specific PCR, using primers MJD8
(5-GATTACAAATTTACTTAAGAG-3) or MJD9 (5-GAT-
TACAAATTTACTTAAGAT-3) combined with MJD6
(5-GACAGAGTTCACATCCATGTG-3). The allele-spe-
cific PCR was performed in the same conditions used for
amplification of the CAG repeat, except for the annealing
step, which was performed at 52°C for 30 seconds. The
PCR products were analyzed in a denaturing 6% poly-
acrylamide gel and visualized by means of autoradiogra-
phy. The DNA sequencing was performed using the
primer MJD52a (5-CCAGTGACTACTTTGATTCGT-3)
to determine the genotype for the C987GG/G987GG poly-
morphism in a few individuals used as controls in the al-
lele-specific PCR. Sequencing with primer MJD6 was
used to determine genotype for polymorphisms TAA1118/
TAC1118 and C1178/A1178 for the same purpose. Reactions
were performed using 5 µL of DNA and a cycle-sequenc-
ing kit (Thermo Sequenase; USB, Cleveland, Ohio) fol-
lowing the manufacturer’s instructions.
Another approach was also used to confirm homoal-
lelism. A 186–base pair (bp) fragment was generated by
means of PCR, with primers MJD1 (5-TGGCCAT-
GATAGGTTATTTTGTGA-3) and MJD2 (5-GGAAA-
ATACATTGTTTCACGAATCAAA-3). This fragment
was purified from agarose gel using an extraction kit
(QIAEX II; QIAGEN, Valencia, Calif) and labeled with
phosphorus 32 (32P) using a labeling kit (Prime-It II Ran-
dom Primer; Stratagene, Cedar Creek, Tex), to be used as
a probe in a Southern blot. The genomic DNA (40 µg) was
digested with the restriction enzyme AluI, and the frag-
ments were separated in a 1% agarose gel (Nusieve 3:1
agarose; FMC BioProducts, Rockland, Me) and blotted in
a nylon membrane (Hybond H-N+; Amersham Pharmacia
Biotech, Buckinghamshire, England) that was hybridized
with the probe at 65°C. This results in bands of approxi-
mately 600 bp for normal alleles and bands larger than
733 bp for expanded alleles. These were visualized by
means of autoradiography.
Figure 3 represents the location of all primers and
restriction sites used in the molecular diagnostic proce-
dure.
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homoallelism, ie, the homozygosity for 2 normal alleles
with exactly the same (CAG)n length. The strategies de-
veloped to overcome these difficulties are presented herein
and may prove useful to other polyglutamine-related dis-
orders.
RESULTS
INTERMEDIATE ALLELES
IN A FAMILY WITH MJD
A family with the MJD mutation was identified, where
the index case was a 69-year-old man (IV:7 in Figure 2).
Age at onset was 45 years with gait imbalance, followed
some years later by diplopia, dysarthria, and dysphagia.
He used a wheelchair since 54 years of age, due to se-
vere cerebellar ataxia. He had a complete limitation of
upward movements of his eyes and partial limitation
of lateral movements, without lid retraction or nystag-
mus. A bilateral facial palsy with atrophy and fascicula-
tions was evident, as well as a moderate, generalized
muscle weakness and atrophy of the limbs with are-
flexia. Except for a brisk jaw jerk, no corticospinal signs
were present, and no dystonia. The clinical picture cor-
responded to a classic subtype 3.
The proband’s oldest son (V:4, born in 1952) was
also affected, with difficulty walking since 32 years of age,
followed 2 years later by dysarthria and diplopia. At 45
years of age, with 13 years of evolution of the disease,
he still had an independent gait but was unable to work.
He showed a moderate cerebellar ataxia, more marked
in the gait and in the lower limbs. A coarse nystagmus
was present. Vertical eye movements were limited, and
some contraction fasciculations of the face were ob-
served. Muscular strength was normal. All deep-tendon
reflexes were exaggerated, but plantar reflexes were nor-
mal, and there was no spasticity. This clinical picture cor-
responded to a subtype 2. The other son (V:5) and the
daughter (V:6) of the proband had normal results of neu-
rologic examinations at 35 and 32 years of age, respec-
tively; the proband’s wife (IV:8) had normal results of
neurologic examination at 67 years of age.
The proband (IV:7) carried an expanded allele
with 68 CAG repeats (Figures 1 and 2). His oldest son
(V:4) carried an expanded allele of 71 repeats, and, in
addition, an allele with 51 repeats (Figures 1 and 2).
The unaffected 35-year-old son (V:5) carried the pater-
nal normal allele with 21 repeats and the intermediate
allele with 51 repeats, whereas the 32-year-old unaf-
fected daughter (V:6) carried 2 normal alleles (21 and
23 CAGs). Their unaffected mother (IV:8) had a normal
allele (23 repeats) and the intermediate allele of 51
repeats.
The length of the (CAG)n in 12 other members on
the maternal side of the family is shown in Figure 2; all
were thought, owing to history, not to have MJD. On
examination, all but 4 were considered healthy. Two
sisters had juvenile parkinsonism (IV:1 and IV:2), and 1
male member was bedridden due to spinal cord injury
(III:12); all 3 had 2 normal alleles. One female member
(III:11), however, who was bedridden after a stroke,
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Figure 1. Analysis of (CAG)n length in a pedigree with Machado-Joseph disease (families MJD75 and MJD75b). N indicates normal alleles; E, expanded alleles;
and I, intermediate alleles. Family members designated on the right side are depicted in Figure 2.
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Figure 2. Pedigree with Machado-Joseph disease (family MJD75b). Other
than the proband of family MJD75 (IV:7) (arrow) and his son (V:4), only 1 of
the members of the maternal side of the family available for study carried an
expanded allele (III:11). CAG repeats are indicated for all members
undergoing molecular diagnostic procedure. Individuals represented by
barred symbols presented neurologic symptoms not associated with MJD
and were not carriers of the mutation. The allele with 51 CAG repeats was
stable on 2 transmissions and not associated with the disease on its own.
Squares indicate male members; circles, female members; and slash,
deceased.
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had an expanded allele with 63 CAG repeats. She was
aged 85 years at the time of examination and had been
in good health until 78 years of age, when she had a
stroke with right-sided hemiparesis and speech difficul-
ties. Since then, she had been unable to walk without
assistance. For 3 years, her difficulties walking and
speaking worsened. Dysphagia was noticed for the
first time at the time of observation. She presented with
cerebellar ataxia and limitation of upward gaze. There
was a moderate atrophy of the hands and legs, with
generalized fasciculations, contrasting with muscular
weakness only on the right side (probably due to her
previous stroke). In conclusion, along with mental
deterioration, advanced age, and her history of diabetes
(probably associated with the occurrence of stroke and
the peripheral neuropathy), cerebellar ataxia combined
with anterior horn signs could have been developing
for 3 to 4 years, corresponding to a very-late-onset type
3 MJD.
HAPLOTYPES ASSOCIATED WITH
INTERMEDIATE AND EXPANDED ALLELES
IN FAMILY MJD75b
The intragenic markers A669TG/G669TG, C987GG/
G987GG, TAA1118/TAC1118, and C1178/A1178 were used to de-
fine the haplotypes associated with the intermediate and
expanded alleles in the family under study. The 51 CAG
repeat coming from the unaffected mother (IV:8) was as-
sociated with the same haplotype as the expanded allele
coming from the affected father (IV:7), GGCA. The ex-
panded allele present in the 85-year-old relative (III:11)
was also associated with haplotype GGCA.
LENGTH OF THE (CAG)n TRACT IN THE MJD1
GENE IN A CONTROL POPULATION
The distribution of (CAG)n tract length in 302 chromo-
somes of control individuals born in the same district
where the individual with the 51 CAG repeat originated
is shown in Figure 4. The largest allele found was 37
CAG repeats. No intermediate alleles were found in this
sample.
APPARENT HOMOALLELISM OF THE MJD1 GENE
IN MEMBERS OF MJD FAMILIES
We have performed a total of 204 diagnostic and predic-
tive tests. According to our results, 107 family members
carried an expansion, 79 had 2 normal alleles of differ-
ent size, and 21 (10.3%) were apparently homoallelic,
ie, had 2 normal alleles with the same (CAG)n size. When
these 21 individuals underwent typing for 3 intragenic
polymorphisms of the MJD1 gene to try to distinguish
the 2 normal chromosomes (Figure5), in 2 cases (9.5%)
the distinction was possible using polymorphism C987GG/
G987GG; in 4 (19.0%), using A1178/C1178; and in 18 (85.7%),
using TAA1118/TAC1118. In combination, these 3 intra-
genic polymorphisms allowed for the distinction of both
normal alleles in all 21 cases of homoallelism.
Results of Southern blot analysis also confirmed that
none of these individuals carried an expanded allele (an
example is shown in Figure 6).
COMMENT
The molecular diagnosis of MJD is currently based on
the determination of the (CAG)n length in the MJD1 gene.
If someone carries alleles with more than 60 CAG re-
peats, one can predict with some certainty that if the per-
son lives long enough, the disease will develop in this
individual, although it is not possible to establish at what
age symptoms will begin. Below this limit, there are re-
ports of 3 patients with alleles containing 56, 55, and 54
CAG repeats,32-34 making the last one the shortest CAG
repeat known to date in patients.
Precision of size determination has its limitations;
although we can apply more accurate methods using
densitometry to select the peak with the largest area
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Figure 3. Position of primers and restriction sites used in the molecular
diagnostic procedures. MJD indicates Machado-Joseph disease (MJD);
ASP, allele-specific polymerase chain reaction analysis.
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Figure 4. Distribution of (CAG)n length in a sample of the healthy population
(n=320) obtained from the region of origin of family MJD75. No
intermediate alleles were found.
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and using a cloned, sequenced allele as control, one still
has to consider that somatic mosaicism exists, with dif-
ferences in (CAG)n length between lymphocytes (where
length is usually measured) and central nervous system
cells, as well as among subpopulations of lymphocytes.
An error of ±1 CAG repeat is considered acceptable. In
addition, (CAG)n size on its own is not useful as a more
precise predictor of outcome. Although the variability
in clinical presentation is partly explained by the length
of the expanded allele, this inverse correlation is incom-
plete and not applicable for prediction of age at onset or
clinical presentation.3,25,26 For that reason, the sizes of
the alleles are not usually communicated to the consul-
tant. We believe it is important, however, to determine
and to keep an accurate record of the sizes of normal
and expanded alleles, since the molecular diagnosis of
MJD is still in a research phase. In the future, knowl-
edge of other factors affecting disease onset and pro-
gression, eg, environmental agents or modifier genes,
may contribute to a more accurate prediction.
To illustrate this point, we describe herein an MJD1
allele with a repeat length not previously encountered. Al-
though studies in several different populations had shown
a wide gap between the normal (12-44 CAG repeats) and
the disease (61-87 CAG repeats) range, these limits are ex-
pected to change with the increasing size of our sample.
The present identification of a formerly undescribed “in-
termediate” allele containing 51 CAG repeats was the source
of a potential problem for genetic counseling, since we are
not able to predict whether or not the disease will develop
in an individual carrying this allele.
The study of the nuclear family in which this allele
with 51 CAG repeats was found suggested, however, that
this allele might not be pathogenic. First, the 67-year-
old transmitting mother was still unaffected. Second, the
individual carrying this allele in addition to a full expan-
sion did not have a particularly severe clinical presenta-
tion or juvenile onset, as could possibly be expected in a
homozygous patient.35-37 Third, this allele was stable on
at least 2 transmissions. The reduced number of cases
with the allele does not, however, allow us to establish
this conclusion with certainty. When we studied other
living members of this family, no other individuals car-
rying the allele with 51 CAG repeats were found. We did,
however, find an expanded allele with 63 CAG repeats
in an 85-year-old woman (Figure 2) in whom the MJD
phenotype had not been detected previously, possibly only
because of masking by the sequelae of a previous stroke
and a diabetic neuropathy.
The alleles with 51 and 63 CAG repeats share the
same intragenic haplotype (GGCA) and may have a com-
mon origin. We cannot determine, however, whether the
51-CAG allele resulted from the contraction of a previ-
ously expanded allele, or whether the ancestral allele
was of intermediate size and expanded only in 1
branch of the family. However, the GGC haplotype
(not including the polymorphism C/A1178) is known to
be the most common in the healthy population in Por-
tugal and corresponds to a small subgroup of the Por-
tuguese families with MJD, namely those originating
from the island of Sa˜o Miguel and those in the Tagus
River Valley.38,39
In a previous screening of a large control popula-
tion from all districts of Portugal (2000 chromosomes,
100 per district) (P.M., M.do C.C., A.F., C.S.S., Laura
Guimara˜es, Alda Sousa, PhD, and J.S., unpublished data,
August 2001), we have found no alleles larger than 36
CAG repeats, suggesting that intermediate alleles must
be quite uncommon. After an additional control sample
(320 chromosomes) from the very district in the Tagus
River Valley where these families originated (where preva-
lence of MJD is 80 times that of the rest of the country)
underwent screening, no intermediate alleles were found.
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Figure 5. Frequency of genotypes for 3 intragenic polymorphisms in the gene for Machado-Joseph disease among the 21 homoallelic individuals identified in the
context of our diagnostic and predictive testing program. The TAA1118/TAC1118 polymorphism has the highest frequency of heterozygosity, but only the combination of all
3 polymorphisms allowed for the distinction of 2 different normal alleles in all cases. Polymorphisms are described in the “Subjects, Materials, and Methods” section.
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Figure 6. Southern blot analysis of the (CAG)n-containing segment of the
gene for Machado-Joseph disease. bp indicates base pair.
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In Huntington disease, nonpenetrance with inter-
generational instability for alleles with 29 to 35 CAG re-
peats and low penetrance for alleles with 36 to 39 CAG
repeats were described.40,41 It is possible that the same
will occur for intermediate alleles in MJD, but further stud-
ies are needed to clarify this question.
It was also suggested that smaller expansions could
be associated with unusual clinical presentations of MJD,
such as autonomic dysfunction (present in a patient with
an allele with 56 CAG repeats, combined with cerebel-
lar ataxia),32 progressive proximal weakness and sen-
sory disturbances (in a patient with an allele with 54 CAG
repeats),34 or parkinsonian features42 (type 4 cases con-
firmed by results of molecular testing had average size
alleles, with 61 and 71 CAG repeats). Other presenta-
tions that have been suggested for MJD include pure cer-
ebellar ataxia and spastic paraplegia phenotypes.43,44 In
this context, the 2 sisters from pedigree MJD75b with ju-
venile parkinsonism carried 2 normal alleles; in fact, the
consanguinity of their parents may suggest that another
(possibly recessive) mutation might be the cause of their
disease.
Another important source of ambiguity in the mo-
lecular testing of MJD was the relatively high frequency
of apparent homoallelism (ie, homozygosity for exactly
the same size CAG repeat). Given the highly polymor-
phic nature of repetitive tracts, it is not surprising that
most of the individuals with 2 normal alleles at the MJD1
locus (homozygous in the classic mendelian sense) have
2 alleles with different size CAG repeats (heteroallelism).
The exclusion of the disease is very clear in these cases,
and the interpretation of the molecular test results does
not raise major difficulties. Approximately 10% of cases
of homoallelism for the normal allele were found, how-
ever, in our diagnostic and predictive tests. Although PCR
was systematically repeated in every such case, and large
expansions were used as positive controls, it is impos-
sible to completely exclude nonamplification of an ex-
panded allele, because of either extremely large size or
the presence of polymorphisms in the primer-annealing
regions, leading to false-negative results such as have been
described in Huntington disease.45 One case of homoal-
lelism was found in an instance of prenatal diagnosis, cre-
ating a particularly delicate situation, given time con-
straints and the dependence of the parents’ decision to
proceed with or to terminate the pregnancy on the sta-
tus of the fetus regarding the MJD mutation.46 In these
cases, to confirm that we are in the presence of cases of
true homoallelism, our proposed approach (Figure 7)
is (1) to confirm, whenever possible, that it was com-
patible with the parents’ genotypes, ie, that it was pos-
sible for the individual to carry 2 alleles of the same size;
(2) to check the population frequency of that allele (this
should be mentioned in the report); (3) to determine the
intragenic haplotypes in both chromosomes (the 2 nor-
mal chromosomes carrying repetitive CAG tracts of the
same length might be associated with different haplo-
types); and (4) to now use, in addition, a molecular
method not dependent on PCR, which has allowed us
to exclude retrospectively the presence of an expansion
in the MJD1 gene in all cases of homoallelism in study,
thus confirming the results obtained with the intragenic
polymorphisms.
CONCLUSIONS
We have tried to address the major difficulties found while
testing for a genetic disease largely still under study, such
as MJD. We suggest specific solutions for these problems,
and reinforce the need for permanent interaction between
the diagnostic services and the research process.
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Determination of (CAG)n Size
1 Band in Normal Range
Heterozygosity Homozygosity
Report "Normal" Southern Blot
Report "Normal" Report "Affected"
Report "Normal" Report "Affected"
2 Bands in Normal Range 1 Band in Normal Range
1 Band in Abnormal Range
1 Band in Normal Range 1 Band in Normal Range
1 Band in Abnormal Range
Type Intragenic Polymorphisms in This Order:
1. TAA1118/TAC1118
2. C1178/A1178
3. C987GG/G987GG
Figure 7. Flowchart for the molecular diagnosis of Machado-Joseph disease.
Polymorphisms are described in the “Subjects, Materials, and Methods”
section.
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